Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ... CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...
Medscape: Impact of New Approvals on CML Treatment: Insights From ASH 2024 Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment ... Medscape: ASH 2024: Previewing Key Updates and Novel Therapies for Chronic Myeloid Leukemia Lindsay A. Rein, MD, is excited to hear discussions about new data on the treatment of chronic myeloid leukemia (CML) presented at the upcoming 2024 ASH Annual Meeting and Exposition, particularly the ...
cml therapies, ASH 2024: Previewing Key Updates and Novel Therapies for Chronic Myeloid Leukemia Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...
